Linda J. Nicholson

TL;DR: The prospects for novel approaches in the prevention, diagnosis and treatment of malignant disease based on ASS1 pathophysiology and its rate‐limiting product, arginine are examined.

TL;DR: Evidence that cancer can originate from normal stem cells or closely related descendants is discussed, and the implications for successful cancer therapies are discussed, concentrating on the self‐renewal pathways (Wnt, Notch, and Hedgehog), aldehyde dehydrogenase activity, EMT, miRNAs, and other epigenetic modifiers as potential targets for therapeutic manipulation.

TL;DR: In this article, the authors discuss the basis of cancer stem cells resistance to radiotherapy and chemotherapy and highlight the roles of ABC transporters, aldehyde dehydrogenase (ALDH) activity, intracellular signalling pathways, the DNA damage response, hypoxia and proliferative quiescence as being significant determinants.

TL;DR: The results establish epigenetic inactivation of ASS1 as a determinant of response to platinum chemotherapy and imply that transcriptional silencing ofASS1 contributes to treatment failure and clinical relapse in ovarian cancer.

TL;DR: This review assesses the utility of recognizing cancer stem cells by virtue of high expression of aldehyde dehydrogenases (ALDHs), probably significant determinants of cell survival through their ability to detoxify many potentially cytotoxic molecules, and contributing to drug resistance.